Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06413277 · ClinicalTrials.gov registry record

Targeting the Conus Medullaris With ECAP-Controlled Closed-Loop SCS for Treatment of Chronic Pelvic Pain: HOPE Trial

A clinical trial of Chronic Pelvic Pain and Pudendal Neuralgia, sponsored by Ainsworth Institute of Pain Management.

Recruiting
Registry status
20
Enrollment target
1
Study location

NCT06413277 is a study of Chronic Pelvic Pain and Pudendal Neuralgia that is actively recruiting participants, run by Ainsworth Institute of Pain Management. The registered enrollment target is 20 participants, below the 334-participant average among 8 other Chronic Pelvic Pain trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06413277, a study of Chronic Pelvic Pain and Pudendal Neuralgia, is actively recruiting participants, sponsored by Ainsworth Institute of Pain Management.

RECRUITING
Registry status
20 participants
Enrollment target
1
Study location

Study Summary

The aim of the study is to evaluate the effectiveness of using ECAP (electrically evoked compound action potential)-controlled CL (closed-loop) SCS (spinal cord stimulation) to treat chronic pelvic pain by stimulating an area in the spine called the conus medullaris (the lowermost tapering extremity of the spinal cord).

Interventions

  • DEVICE Saluda Evoke Smart SCS System

Study Locations (1)

New York

  • Ainsworth Institute of Pain Management - New York

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-02-05
Est. Completion 2027-01-01

What the Registry Record Tells You About NCT06413277

The ClinicalTrials.gov registry entry for NCT06413277 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 334-participant average among 8 other Chronic Pelvic Pain trials with a reported enrollment target (94% lower). The listed sponsor is Ainsworth Institute of Pain Management, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Pelvic Pain appearing as the primary indexed condition, and to 1 intervention - of which Saluda Evoke Smart SCS System is the first listed.

NCT06413277 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT06413277 about?

NCT06413277 is a clinical study titled "Targeting the Conus Medullaris With ECAP-Controlled Closed-Loop SCS for Treatment of Chronic Pelvic Pain: HOPE Trial". The aim of the study is to evaluate the effectiveness of using ECAP (electrically evoked compound action potential)-controlled CL (closed-loop) SCS (spinal cord stimulation) to treat chronic pelvic pain by stimulating an area in the spine called the conus medullaris (the lowermost tapering extremity...

What is the current status of trial NCT06413277?

This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2024-02-05. Estimated completion is 2027-01-01.

What conditions does trial NCT06413277 study?

This clinical trial studies the following conditions: Chronic Pelvic Pain, Pudendal Neuralgia.

What interventions are being tested in trial NCT06413277?

The interventions under investigation include: Saluda Evoke Smart SCS System (DEVICE).

Who is sponsoring clinical trial NCT06413277?

This trial is sponsored by Ainsworth Institute of Pain Management, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06413277 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Pelvic Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.